Glenmark Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)
Glenmark Pharmaceuticals Ltd · Outcome · 05 Nov 2026, 10:34 pm
Glenmark Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 42,473 (-29.8% YoY | +5.7% QoQ) ■ EBITDA: 8,638 (-63.4% YoY | +7.3% QoQ) ■ EBITDA Margin (%): 20.3 (-1868 bps YoY | +31 bps QoQ) ■ PAT: 2,638 (-56.8% YoY | -45.4% QoQ) ■ EPS (INR): 9.34 (-56.8% YoY | -45.4% QoQ)
Original exchange filing (PDF)
More announcements from Glenmark Pharmaceuticals Ltd
- Ichnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301 · 18 Nov 2026
- Glenmark Pharmaceuticals Inc., USA Launches Authorised Generic of INLYTA (axitinib) Tablets, 1 mg and 5mg · 16 Nov 2026
- Schedule of Schedule of Analyst/ Institutional Investor Meetings · 10 Nov 2026
- Initmation of Schedule of Analyst/ Institutional Investor Meetings · 10 Nov 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings · 10 Nov 2026
- Intimation of Schedule of Analyst / Institutional Investor Meetings · 10 Nov 2026
- Transcript of the Earnings Call · 09 Nov 2026
- Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 · 06 Nov 2026
